Current image-based deep learning models that predict the benefits of immunotherapy in non-small cell lung cancer (NSCLC) require high-performance hardware. We aimed to develop and externally validate a clinician-operable prognostic model that integrates clinical and imaging data in a format usable by clinicians on standard central-processing-unit (CPU) hardware. This multicenter study included 1,379 patients with NSCLC treated with immunotherapy from five Chinese hospitals and the Memorial Sloan-Kettering (MSK) Cancer Center. A pairwise association encoder (PAE) converted routinely collected baseline clinical variables into edge weights of a patient-similarity graph, while radiomics features extracted from pretreatment chest computed tomography (CT) were embedded as node attributes in a Deep Hypergraph for NSCLC (DHGN). DHGN was trained on progression-free survival (PFS) and validated on overall survival (OS). Model performance was compared with three established control models and a published deep learning benchmark. Ten thoracic oncology experts independently implemented and tested each pipeline. Trained on PFS, DHGN yielded C-indices of 0.72, 0.71, and 0.71, and 0.70, 0.71, and 0.69 when validated on OS. DHGN outperformed the clinical-only, radiomics-only, composite, and EfficientNetV2 models for both endpoints (all P 24 months and those unlikely to reach 12 months, which was superior to tumor mutation burden (TMB) and PD-L1 expression. Higher DHGN scores strongly predicted longer survival outcomes (hazard ratio: 0.10, 95% CI: 0.07–0.16, P < 0.0001) and improved the prognostic accuracy of patient stratification based on PD-L1 expression. Based on clinicians’ practical deployment, the DHGN significantly reduced the operational complexity and computational requirements ( P < 0.01) for model development and application in clinical settings. In conclusion, we proposed a clinician-friendly population graph model that fuses baseline clinical data with CT radiomics on widely available CPU hardware accurately stratifies NSCLC patients for immunotherapy benefits, potentially redefining benchmarks for non-invasive prognostic biomarkers and enabling broader clinical translation.
Song et al. (Mon,) studied this question.